1000207-52-2 Usage
Uses
Given the lack of specific applications mentioned in the provided materials, the following uses are speculative based on the compound's structure and potential pharmacological activity:
Used in Pharmaceutical Industry:
Tert-butyl 4-(2-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)piperidine-1-carboxylate could be used as a pharmaceutical agent for [specific therapeutic area] due to its unique molecular structure and the presence of pharmacologically active groups. tert-butyl 4-(2-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)piperidine-1-carboxylate's potential activity as a pharmaceutical agent is suggested by the presence of the piperidine ring and the cyclopenta[d]pyrimidin-4-ylamino group, which may contribute to its interaction with biological targets and therapeutic effects.
Used in Drug Development Research:
In the field of drug development research, tert-butyl 4-(2-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)piperidine-1-carboxylate may serve as a starting point for the design and synthesis of new compounds with improved pharmacological properties. Its unique structure and potential activity as a pharmaceutical agent make it a valuable candidate for further exploration and optimization to develop novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1000207-52-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,2,0 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1000207-52:
(9*1)+(8*0)+(7*0)+(6*0)+(5*2)+(4*0)+(3*7)+(2*5)+(1*2)=52
52 % 10 = 2
So 1000207-52-2 is a valid CAS Registry Number.
1000207-52-2Relevant academic research and scientific papers
Fang, Yuanying,Xiong, Lijuan,Hu, Jianguo,Zhang, Shaokun,Xie, Saisai,Tu, Liangxing,Wan, Yang,Jin, Yi,Li, Xiang,Hu, Shaojie,Yang, Zunhua
, p. 103 - 111 (2019)
A novel series of fused pyrimidine derivatives were designed, synthesized and evaluated as GPR119 agonists. Among them, cyclohexene fused compounds (tetrahydroquinazolines) showed greater GPR119 agonistic activities than did dihydrocyclopentapyrimidine and tetrahydropyridopyrimidine scaffolds. Analogues (16, 19, 26, 28, 42) bearing endo-N-Boc-nortropane amine and fluoro-substituted aniline exhibited better EC50 values (0.27–1.2 μM) though they appeared to be partial agonists.
PYRIMIDINE AND QUINAZOLINE DERIVATIVES
-
Page/Page column 71, (2008/06/13)
This invention is concerned with compounds of the formula ( l ) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
